Analytical Data
-
Gene name
DUX4
- Application
-
Alternative Names
Double homeobox protein 10
-
Species
Human
-
Source
E. coli
-
Tag
N- His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9UBX2
-
Expression Region
327-424aa
-
Molecular Weight
14.3 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
Research on the DUX4 recombinant protein has gained significant attention due to its association with facioscapulohumeral muscular dystrophy (FSHD), a genetic disorder characterized by progressive muscle weakness and atrophy. DUX4, a double homeobox transcription factor, is normally expressed only in the early stages of development but becomes aberrantly activated in FSHD. The pathogenic role of DUX4 in muscle cells primarily stems from its ability to induce apoptosis and disrupt muscle cell function. Consequently, researchers have focused on understanding the molecular mechanisms underlying DUX4 activity, which includes its interaction with various cellular pathways and target genes. By generating recombinant DUX4 protein, scientists aim to elucidate its structure, function, and the downstream effects it exerts in affected muscle tissues. This research not only helps clarify the pathological processes involved in FSHD but also paves the way for potential therapeutic strategies, including gene silencing and targeted treatment approaches aimed at mitigating the deleterious effects of DUX4. Overall, the investigation of DUX4 recombinant protein serves as a crucial step in unraveling the complexities of FSHD and advancing the development of effective interventions for this debilitating condition.
